Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 in Primary Sjögren's Syndrome
NCT02149420Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2014
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ianalumab in primary Sjögren's syndrome (3 arms), sponsored by Novartis. Primary endpoints: EULAR Sjögren's Syndrome Disease Activity Index at Week 12 and Overall Incidence of Adverse Events at Week 24. Started May 2014; status: completed.
02
Drugs
ianalumab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT02149420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02149420.